CTOs on the Move

LifeCare Hospitals

www.lifecare-hospitals.com

 
LifeCare Hospitals is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. LifeCare Hospitals is based in Plano, TX. You can find more information on LifeCare Hospitals at www.lifecare-hospitals.com
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Axium Healthcare Pharmacy, Inc

Axium Healthcare Pharmacy, Inc. is a nationwide, privately-held Clinical Specialty Pharmacy licensed to operate in all 50 states. Axium Healthcare Pharmacy, Inc.

Canopy Health Insurance

We do things differently here. Unlike old-school health insurance, ours is refreshingly simple, wallet-friendly and designed for your life. It’s health insurance you just might like.

Electronic Waveform Lab Inc

Electronic Waveform Lab Inc is a Huntington Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Grant and Associates

Grant and Associates is a Olympia, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.